Genematrix, acquires COVID-19 vaccine substitute materials and secured superior neutralizing antibodies for commercial vaccines > news

본문 바로가기
ENG
Home  >  PR  >  News
NEWS

Genematrix, acquires COVID-19 vaccine substitute materials and secured superior neutralizing antibodies for commercial vaccines

페이지 정보

작성일 21-10-05 00:00

본문

 -

회원로그인

회원가입